This is an on demand report, it will take 20 to 25 working days to complete
The ‘Liver Cancer Partnering 2007-2012’ provides understanding and access to the liver cancer partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of liver cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This data driven report contains over 25links to online copies of actual liver cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of liver cancer partnering trends.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in liver cancer partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading liver cancer deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of liver cancer partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of liver cancer technologies and products.
Liver Cancer Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to liver cancer trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in liver cancer dealmaking in the biopharma industry since 2007
- Access to summary headline, upfront, milestone and royalty data
- Access to over 25 liver cancer contract documents
- The leading lymphoma deals by value since 2007
In Liver Cancer Partnering 2007-2012, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Liver Cancer Partnering 2007-2012 provides the reader with the following key benefits:
- In-depth understanding of liver cancer deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 25 actual liver cancer deals entered into by the world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
- About Current Partnering
Current Partnering was established in 2007 and has become the leading publisher of deal term reports within the life sciences. Designed to translate research into commercial success, Current Partnering provides an opportunity for the dissemination of the latest trends in partnering activity across the life sciences.
Current Partnering report titles cover all aspects of partnering best practice and deal terms, providing users with the information and insight required to optimise their partnering activities
Table of Content
Chapter 1 Introduction
Chapter 2 Trends in liver cancer partnering
2.2. Liver cancer partnering over the years
2.3. Bigpharma liver cancer dealmaking activity
2.4. Liver cancer partnering by deal type
2.5. Liver cancer partnering industry sector
2.6. Liver cancer partnering by stage of development
2.7. Liver cancer partnering by technology type
2.8. Disclosed financial deal terms for liver cancer partnering
2.8.1 Liver cancer headline values
2.8.2 Liver cancer upfront payments
2.8.3 Liver cancer milestone payments
2.8.4 Liver cancer royalty rates
Chapter 3 Leading liver cancer deals
3.2. Top liver cancer deals by value
3.3. Top liver cancer deals involving bigpharma
Chapter 4 Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form Reports
Figure 1: Liver cancer partnering since 2007
Figure 2: Bigpharma top 50 liver cancer deals 2007 to 2011
Figure 3: Bigpharma liver cancer deal frequency 2007 to 2011
Figure 4: Liver cancer partnering by deal type since 2007
Figure 5: Liver cancer partnering by industry sector since 2007
Figure 6: Liver cancer partnering by stage of development since 2007
Figure 7: Liver cancer partnering by technology type since 2007
Figure 8: Liver cancer deals with a headline value
Figure 9: Liver cancer deals with upfront payment values
Figure 10: Liver cancer deals with milestone payments
Figure 11: Liver cancer deals with royalty rates, %
Figure 12: Top liver cancer deals by value since 2007
Figure 13: Top liver cancer deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions